**Background**
Vaginal candidiasis is a common fungal infection caused primarily by Candida albicans and other Candida species. These opportunistic pathogens can cause significant inflammation, itching, and discomfort, impacting the quality of life for a large number of women. The management of these infections requires potent antifungal agents capable of disrupting the fungal cell membrane to eliminate the pathogen. Imidazole derivatives have long been utilized in clinical settings due to their ability to interfere with the biosynthesis of essential fungal sterols. In this context, we will introduce an imidazole antifungal agent – Butoconazole.
**Definition**
Butoconazole is an imidazole antifungal agent active against Candida spp., specifically effective against vaginal infections caused by Candida albicans.
**Mechanism of Action**
According to the Butoconazole description, this compound is presumed to function similarly to other imidazole derivatives via the inhibition of steroid synthesis. Specifically, Butoconazole in vitro activity involves the inhibition of the conversion of lanosterol to ergosterol. This enzymatic blockade results in a significant change in the lipid composition of the fungal cell membrane. Such structural alterations increase cell permeability, which ultimately leads to the osmotic disruption or growth inhibition of the fungal cell. For researchers requiring specific Butoconazole technical information, these mechanisms highlight its utility in studying fungal membrane dynamics.
**In Vitro Studies**
The pharmacological profile of Butoconazole is characterized by its ability to target the fungal cell wall. While specific IC50 values for various strains are not provided, it is established that the compound effectively inhibits the growth of Candida albicans by altering membrane integrity. The Butoconazole Formula (C19H18Cl3N3O3S) and its molecular weight of 474.79 contribute to its stability and efficacy as a topical antifungal agent. In conclusion, Butoconazole is a potent imidazole antifungal agent that serves as a critical tool for research into the treatment of Candida-induced infections.
Keywords
Butoconazole, 64872-77-1, RS 35887, RS35887, RS-35887, Fungal, Inhibitor, inhibitor, inhibit
References
[1] Anik ST, et al. Extreme vertexes design in formulation development: solubility of butoconazole nitrate in a multicomponent system. J Pharm Sci. 1981;70(8):897-900.
[2] Pharmacology refers to the chemical makeup and behavior of GYNAZOLE 1 (butoconazole nitrate cream).